Similar articles for PMID: 27569869

Year	Number of Results
1998	1
2000	1
2002	2
2003	1
2004	4
2005	5
2006	5
2007	3
2008	10
2009	8
2010	10
2011	10
2012	7
2013	7
2014	8
2015	20
2016	27
2017	37
2018	27
2019	25
2020	24
2021	17
2022	17
2023	15
2024	0

1

The role of pharmacogenetics in capecitabine efficacy and toxicity.

Lam SW, Guchelaar HJ, Boven E. Lam SW, et al. Cancer Treat Rev. 2016 Nov;50:9-22. doi: 10.1016/j.ctrv.2016.08.001. Epub 2016 Aug 10. Cancer Treat Rev. 2016. PMID: 27569869 Review.

2

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH. Meulendijks D, et al. Lancet Oncol. 2015 Dec;16(16):1639-50. doi: 10.1016/S1470-2045(15)00286-7. Epub 2015 Oct 23. Lancet Oncol. 2015. PMID: 26603945 Review.

3

Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.

Queckenberg C, Erlinghagen V, Baken BC, Van Os SH, Wargenau M, Kubeš V, Peroutka R, Novotný V, Fuhr U. Queckenberg C, et al. Cancer Chemother Pharmacol. 2015 Nov;76(5):1081-91. doi: 10.1007/s00280-015-2840-6. Epub 2015 Aug 5. Cancer Chemother Pharmacol. 2015. PMID: 26242222 Clinical Trial.

4

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348537

5

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.

Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM. Loganayagam A, et al. Br J Cancer. 2013 Jun 25;108(12):2505-15. doi: 10.1038/bjc.2013.262. Epub 2013 Jun 4. Br J Cancer. 2013. PMID: 23736036 Free PMC article.

6

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.

Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, Miolo G, Mini E, Nobili S, Lonardi S, Pella N, Lo Re G, Montico M, Roncato R, Dreussi E, Gagno S, Cecchin E. Toffoli G, et al. Int J Cancer. 2015 Dec 15;137(12):2971-80. doi: 10.1002/ijc.29654. Epub 2015 Jul 14. Int J Cancer. 2015. PMID: 26099996 Free article.

7

Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.

Roberto M, Romiti A, Botticelli A, Mazzuca F, Lionetto L, Gentile G, Paris I, Falcone R, Bassanelli M, Di Pietro FR, Onesti CE, Anselmi E, Macrini S, Simmaco M, Marchetti P. Roberto M, et al. Eur J Clin Pharmacol. 2017 Feb;73(2):157-164. doi: 10.1007/s00228-016-2160-8. Epub 2016 Nov 18. Eur J Clin Pharmacol. 2017. PMID: 27864592

8

Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.

Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, Guchelaar HJ, Smits PH, Beijnen JH, Punt CJ, Schellens JH, Cats A. Deenen MJ, et al. Clin Cancer Res. 2011 May 15;17(10):3455-68. doi: 10.1158/1078-0432.CCR-10-2209. Epub 2011 Apr 15. Clin Cancer Res. 2011. PMID: 21498394 Free article.

9

Identification of new SNPs associated with severe toxicity to capecitabine.

Pellicer M, García-González X, García MI, Robles L, Grávalos C, García-Alfonso P, Pachón V, Longo F, Martínez V, Blanco C, Iglesias I, Sanjurjo M, López-Fernández LA. Pellicer M, et al. Pharmacol Res. 2017 Jun;120:133-137. doi: 10.1016/j.phrs.2017.03.021. Epub 2017 Mar 27. Pharmacol Res. 2017. PMID: 28347776

10

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers CMPW, Soesan M, Cats A, Schellens JHM. Meulendijks D, et al. Br J Cancer. 2017 May 23;116(11):1415-1424. doi: 10.1038/bjc.2017.94. Epub 2017 Apr 20. Br J Cancer. 2017. PMID: 28427087 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

244 results

Results by year